Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 53164-05-9 Chemical Structure| 53164-05-9
Chemical Structure| 53164-05-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Acemetacin is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.

Synonyms: TVX 1322

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Acemetacin

CAS No. :53164-05-9
Formula : C21H18ClNO6
M.W : 415.82
SMILES Code : O=C(OCC(O)=O)CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3
Synonyms :
TVX 1322
MDL No. :MFCD00151473
InChI Key :FSQKKOOTNAMONP-UHFFFAOYSA-N
Pubchem ID :1981

Safety of Acemetacin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300-H310-H330
Precautionary Statements:P260-P264-P280-P284-P301+P310-P302+P350
Class:6.1
UN#:2811
Packing Group:

Application In Synthesis of Acemetacin

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 53164-05-9 ]

[ 53164-05-9 ] Synthesis Path-Downstream   1~31

  • 1
  • [ 53164-05-9 ]
  • 2-(4-Chlorphenyl)-6-methoxy-4H-3.1-benzoxazinon-4 [ No CAS ]
  • N-(4-Chlor-benzoyl)-5-methoxy-anthranilsaeuremethylester [ No CAS ]
  • <2-(4-Chlor-benzoylamino)-5-methoxy>-benzoyl-2-essigsaeuremethylester [ No CAS ]
  • <2-(4-Chlor-benzoylamino)-5-methoxy>-benzoyl-2-acetoxy-essigsaeure [ No CAS ]
  • 2
  • [ 53164-05-9 ]
  • 2-Acetyl-N-(4-chlor-benzoyl)-4-methoxy-anilin [ No CAS ]
  • N-(4-Chlor-benzoyl)-5-methoxy-anthranilsaeuremethylester [ No CAS ]
  • <2-(4-Chlor-benzoylamino)-5-methoxy>-benzoyl-2-essigsaeuremethylester [ No CAS ]
  • <2-(4-Chlor-benzoylamino)-5-methoxy>-benzoyl-2-acetoxy-essigsaeure [ No CAS ]
  • 3
  • [ 53164-04-8 ]
  • [ 53164-05-9 ]
YieldReaction ConditionsOperation in experiment
97.8% With aluminum (III) chloride; In dichloromethane; N,N-dimethyl-formamide; at 80℃; for 24.0h; a synthetic method of acemetacin, the steps of which areA. 100 g (0.198 mol) of acesulfame benzyl ester was dissolved in 400 mL of dichloromethane, and then 250 mL of N,N-dimethylaniline was added to obtain a solution A.B. 100 mL of dichloromethane was added to 79.2 g (0.594 mol of 1) of A1C13, and solution A was slowly added at zero.C. After the addition is completed, the reaction is raised to room temperature for 55 or 58 or 60 or 63 or 65 minutes. After the reaction is completed, the reaction mixture is poured into ice water, stirred for 28 or 29 or 30 or 31 or 32 minutes, and then filtered to obtain a crude product. acematecinD. The crude acemetacin obtained in the step C is recrystallized from acetone and water (volume ratio of 2:1), decolorized by adding activated carbon, and the crystals are dried at 80 C for 24 hours to obtain 80.4 g of pure Asi. Mesin, the yield is 97.8%. The purity was determined by HPLC to be greater than 99.8%.The other steps are the same as in the first embodiment.
YieldReaction ConditionsOperation in experiment
97.1% EXAMPLE 5 The t-butyl ester of acemetacin (201 mg) was dissolved in 3.5 ml of formic acid and the resultant solution was stirred at room temperature for 3 hours. Formic acid was caused to evaporate under reduced pressure. The residue was taken up in 400 ml of a 1:5 liquid mixture of acetone and benzene and insoluble material was removed by filtration. The solvent was then driven off from the filtrate. The residue was recrystallized from benzene to obtain 172 mg of acemetacin as pale yellowish crystals (yield: 97.1%).
86-91% EXAMPLE 4 Acemetacin 0.003 mole of tetrakis-triphenylphosphine-palladium-(O) is added to 0.03 mole of acemetacin allyl ester in 50 ml of tetrahydrofuran, under nitrogen. 0.3 mole of piperidine is added dropwise at 20-25 C., with stirring, and stirring is then continued for 2 hours at room temperature (check by thin layer chromatography). 200 ml of half-concentrated hydrochloric acid are added dropwise with cooling, the phases are separated off, the aqueous phase is extracted twice with methylene chloride and the combined organic phases are evaporated in vacuo. The residue is recrystallized from toluene. Yield: 86-91% of theory; melting point: 150 C.
EXAMPLE 5 (ACEMETACIN) 0.4 g of p-toluenesulphonic acid is added to 9.6 g of tert.-butyl ester of acemetacin according to example 1 in 30 ml of acetic acid, and the mixture is stirred at 100 C. for 4 to 5 hours. After the mixture has cooled down to room temperature, 50 ml of water are added. Acemetacin precipitates, is filtered off with suction and is recrystallized from acetone/water. Yield: 8.0 g=90.6% of theory of pure product.
EXAMPLE 14 (solution) Polyisobutylene of molecular weight 400,000: 40.00 g Thinly liquid paraffin: 50.00 g Polyterpene resin from alpha-pinene: 10.00 g Acemetacin: 17.65 g Release: about 12% after 6 hours.
Preparation of acemetacin Splitting of the protective group of acemetacin derivative according to the invention The 4-methoxybenzyl ester (5.35 g=0.01 mol) prepared as described above is dissolved in 5.4 g (0.05 mol) of anisole, and 0.73 g (0.02 mol) of glacial acetic acid/HCl (75.9 mg of HCl/ml) is added while stirring and in the absence of moisture. After a reaction time of 5 hours, the conversion is quantitative. 1.8 g (0.023 mol) of ammonium acetate are added to the reaction mixture, the mixture is stirred for 10 minutes, 20 ml of water are added, and stirring is continued for a further 10 minutes. Thereafter, the mixture is extracted with 40 ml of toluene, the organic phase is washed neutral and dried over Na2 SO4, and the solvent is distilled off. The residue is stirred throughly with 200 ml of petroleum ether. Crystals are formed, and are filtered off under suction, washed with petroleum ether and dried. The substance is purified by dissolving it in methylene chloride, adding 80 ml of carbon tetrachloride and distilling off the methylene chloride at 70 C. Acemetacin crystallises at room temperature. Recrystallisation from toluene gave the pure substance in a yield of 2.8 g=67.3% of theory, with a melting point of 150-151 C.
EXAMPLE 7 Acemetacin 31.9 g of acemetacin allyl ester, 100 ml of toluene, 2.3 g of triphenylphosphine and 0.75 g of palladium on charcoal (5% strength) are taken as an initial charge, under nitrogen. 11.9 g of piperidine are added dropwise, with stirring, and the mixture is then stirred for a further 3 hours at 90 C. It is filtered hot and the catalyst is rinsed with hot toluene. The filtrate is evaporated, the residue is taken up in methylene chloride (about 300 ml) and this solution is washed with half-concentrated hydrochloric acid (100 ml) and then with water. After removal of the solvent in vacuo, the residue is recrystallized from toluene. Yield: 27.3 g=94% of theory; melting point: 150

  • 7
  • [ 53164-05-9 ]
  • [ 2882-15-7 ]
  • [ 53-86-1 ]
  • 5-methoxy-2-methylindol-3-yl acetic acid carboxymethyl ester [ No CAS ]
  • [ 74-11-3 ]
  • 8
  • [ 53164-05-9 ]
  • [ 1613-88-3 ]
  • 9
  • [ 19501-58-7 ]
  • [ 53164-05-9 ]
  • 10
  • [ 53164-08-2 ]
  • [ 53164-05-9 ]
  • 11
  • [ 53-86-1 ]
  • [ 53164-05-9 ]
  • 12
  • [ 123-76-2 ]
  • phosphorus pentasulfide [ No CAS ]
  • [ 53164-05-9 ]
  • 13
  • [ 53164-03-7 ]
  • [ 53164-05-9 ]
  • 14
  • 4-Methoxyphenylhydrazin-β-sulfonsaeure Natriumsalz [ No CAS ]
  • [ 53164-05-9 ]
  • 15
  • [ 4665-58-1 ]
  • [ 53164-05-9 ]
  • [ 646511-43-5 ]
YieldReaction ConditionsOperation in experiment
60% With 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; 2-(Dimethylamino)pyridine; Example 56 (N-(2-(Nitrooxy)ethyl)carbamoyl)methyl 2-(1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl)acetate The product of Example 22a, 2-(nitrooxy)ethylammonium nitrate (850 mgs, 5 mmol) and the product of Example 55b (1.68 g, 4 mmol) were reacted with 1-ethyl-3-(3-dimethylaminopropyl) carbamide hydrochloride (EDAC, 4 mmol) and N,N-dimethylaminopyridine (DMAP, following the procedure for Example 55c. The product was purified by column chromatography on silica gel eluding with EtOAc:hexane (1:1) to give the title compound (1.22 g, 60% yield) as white solid. Mp 128-129 C. 1H NMR (300 MHz, CDCl3) delta 7.65 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 6.96 (d, J=2.2 Hz, 1H), 6.87 (d, J=9.0 Hz, 1H), 6.7 (dd, J=9.0 and 2.3 Hz, 1H), 6.1 (d, J=5.1 Hz, 2H), 4.56 (s, 2H), 4.32 (d, J=5.1 Hz, 2H), 3.81 (s, 3H), 3.77 (s, 2H), 3.37 (q, J=5.2 Hz, 2H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) delta 168.9, 168.2, 167.3, 156.1, 139.5, 136.3, 133.5, 131.1 (2*C), 130.8, 130.1, 129.1 (2*C), 115.3, 111.4, 101.0, 70.9, 62.8, 55.7, 36.4, 30.1, 13.3; LRMS (APIMS) m/z 504 (MH+) and 521 (MNH4+).
  • 16
  • [ 145459-16-1 ]
  • [ 53164-05-9 ]
  • [ 646511-41-3 ]
YieldReaction ConditionsOperation in experiment
85% With 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; dmap; triethylamine; In dichloromethane; at 20℃; 55c (N-Methyl-N-(2-(nitrooxy)ethyl)carbamoyl)methyl 2-(1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl)acetate The product of Example 17c (457 mg, 2.5 mmol) was stirred in CH22C2 (10 mL) and Et3N (0.25 mL) was added at room temperature and the reaction mixture was stirred for 10 minutes. Then the product of Example 55b (1.04 g, 2.5 mmol) in CH2Cl2 (10 mL) was added followed by 1-ethyl-3-(3-dimethylaminopropyl) carbamide hydrochloride (EDAC, 0.483 g, 2.5 mmol) and N,N-dimethylaminopyridine (DMAP, 0.305 g, 2.5 mmol). The resulting solution was stirred under nitrogen atmosphere at room temperature overnight. The reaction mixture was diluted with EtOAc, washed with water, aqueous NaHCO3, water, 0.5 N HCl, brine, dried over sodium sulfate, filtered, and the organic extracts were evaporated. The product was purified by column chromatography on silica gel eluding with EtOAc:hexane (1:1) to give the title compound (1.1 g, 85% yield) as white foam. Mp 118-122 C. 1H NMR (300 MHz, CDCl3) delta 7.65 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.5 Hz, 2H), 7.0 (d, J=2.2 Hz, 1H), 6.87 (d, J=9.0 Hz, 1H), 6.65 (dd, J=9.0 and 2.3 Hz, 1H), 4.73 (s, 2H), 4.58 (t, J=5.1 Hz, 2H), 3.83 (s, 3H), 3.81 (s, 2H), 3.67 (t, J=5.1 Hz, 2H), 2.99 (s, 3H), 2.36 (s, 3H); 13C NMR (75 MHz, CDCl3) delta 170.4, 168.2, 166.7, 156.0, 139.1, 136.0, 133.8, 131.1 (2*C), 130.6, 130.5, 129.0(2*C), 114.8, 112.0, 111.8, 101.1, 70.9, 61.5, 55.6, 46.0, 35.6, 29.7, 13.3; LRMS (APIMS) ml/z 534 (MH+).
  • 17
  • [ 75302-98-6 ]
  • [ 53164-05-9 ]
YieldReaction ConditionsOperation in experiment
80% With trifluoroacetic acid; In dichloromethane; at 20℃; for 48.0h; 55b. 2-(2-(1-((4-Chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl)acetyloxy)acetic Acid The product of Example 55a (6.12 g, 13 mmol) was dissolved in CH2Cl2 (50 mL) and TFA (15 mL) was added. The reaction mixture was stirred at room temperature for 2 days. The solvent and TFA were evaporated in vacuo and the residue obtained was dissolved in EtOAc (50 mL) and the solvent evaporated again to remove traces of trifluoroacetic acid. The residue obtained was recrystallized from EtOAc:hexane (1:4) to give the title compound (4.3 g, 80% yield) as a gray colored solid. Mp 137-138 C. 1H NMR (300 MHz, CDCl3) delta 8.93 (br s, 1H), 7.65 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 6.96 (d, J=2.3 Hz, 1H), 6.87 (d, J=9.0 Hz, 1H), 6.6 (dd, J=9.0 and 2.4 Hz, 1H), 4.67 (s, 2H), 3.81 (s, 3H), 3.78 (s, 2H), 2.36 (s, 3H); 13C NMR (75 MHz, CDCl3) delta 172.6, 170.3, 168.4, 155.9, 139.2, 136.1, 133.7, 131.1 (2*C), 130.7, 130.4, 129.1 (2*C), 114.9, 111.8, 111.7, 101.2, 60.5, 55.6, 29.6, 13.4; LRMS (APIMS) m/z 416 (MH+).
  • 18
  • [ 53164-05-9 ]
  • [ 91421-42-0 ]
  • acemetacin [ No CAS ]
YieldReaction ConditionsOperation in experiment
32% With dicyclohexyl-carbodiimide;dmap; In DMF (N,N-dimethyl-formamide); at 20℃; for 96.0h; 0.5 grams (0.0013 mol) of a CPT derivative, 9-nitrocamptothecin, is dissolved in approximately 60 ml of DMF. To this solution is added 0.75 grams (0.0036 mol) of DCC and 0.20 grams (0.0016 mol) of DMAP, and 1.0 grams (0.0024 mol) of 1-(4-chlorobenzyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester (or <strong>[53164-05-9]Acemetacin</strong>) [thus attaching <strong>[53164-05-9]Acemetacin</strong>-yl ] in a three neck round bottom flask with mechanical stiffing under a nitrogen atmosphere at room temperature. After 96 hours, the solvent was removed under vacuum and the residue chromatographically separated on silica, using THF-methylene chloride in the ratio of 1:10 (v/v) as the eluting solvent. The final product, known as CZ207, was obtained as a yellow powder in a 32% yield. The numbering of the side chain is depicted above. [0081] 1H NMR (CDCl3): 1.05(3H, t, J=7.08 HZ, C19 methyl protons), 2.200 2.36(2H, m, C18 methylene protons), 2.50(3H, S, C40CH3), 3.95(3H, S, C29-methoxyprotons), 4.10-4.50(2H, dd, J=17.20, 17.40 HZ, C25-methylene protons), 5.20-5.40(2H, dd, J=17.35, 17.52 HZ, C23methylen protons), 5.65(2H, S, C5methylene protons), 5.68-6.08(2H, dd, J=8.54, 8.58 HZ, C30-H, C31H), 7.25(1H, S, C14H), 7.80(1H, S, C28H), 8.0-8.20(4H, dd, J=8.65, 8.68 HZ, 35-H, C36H, C38H, C39H), 8.35(1H, t, J=7.85 HZ, C11H), 8.80 9.00(2H, dd=8.56, 8.62 HZ, C10H, C12H), 9.68(1H, S, C7-H). 13C: 7.9(C19, 13.2(C40-methyl carbon), 25.5, 29.5, 3.15(C18, C23, C25), 49.2(C29-methoxy carbon), 50.6(C5), 61.4(C17), 67.2(C20), 97.0(C14), 100.8, 112.0, 112.1, 114.5, 121.0, 125.8, 127.0, 128.2, 129.1, 130.5, 131.0, 131.5, 133.6, 135.8, 136.5, 139.5, 145.0, 145.5, 145.6, 148.5, 154.5, 155.8, 156.9, 157.0(C2, C3, C6-C16a, C26-C40), 166.5, 167.5, 170.5(C21, C22, C24). [0082] Mass m/e(relative intensity): 790(m+, weak), 415(40), 139(100), 111(20), 75(5); precise mass for C41H31N14O11Cl: Found 790.170, required 790.169.
  • 19
  • copper(II) acetate [ No CAS ]
  • [ 53164-05-9 ]
  • [ 68-12-2 ]
  • bis(N,N-dimethylformamide)bis-(O,O'-ACM)copper(II) [ No CAS ]
  • bis(N,N-dimethylformamide)tetrakis-μ-(O,O'-ACM)dicopper(II) [ No CAS ]
YieldReaction ConditionsOperation in experiment
at 20 - 35℃; EXAMPLE 1; Synthesis of bis(N,N-dimethytformamide)tetrakis-mu-(O,O'-ACM)dicopper(II) tetrahydrate ([Cu2(ACM)4(DMF)2].4H2O) and bis( N, N-dimethylformamide)bis-(O,O'-ACM)copper(II) dihydrate ([Cu(ACM)2(DMF)2].2H2O)ChemicalsACMH was of pharmaceutical grade and obtained from Sigma Aldrich. All other chemicals were used as supplied. [Cu2(Indo)2(DMA)2] was prepared as reported in Morgan, Y. R.; Turner, P.; Kennedy, B. J.; Hambley, T. W.; Lay, P. A.; Biffin, J. R.; Regtop, H. L; Warwick, B. Inorg. Chim. Acta 2001, 324, 150-161.SynthesisA warm solution of Cu(II) acetate monohydrate (0.24 g, 1.20 mmol) dissolved in DMF (2 ml) was added to a stirred solution of ACMH ( 1.00 g, 2.41 mmol) in DMP (1.5 ml) heated at 35 C. The reaction was maintained at 35 C for a further 2 hr, then stirred at room temperature overnight, during which time a pale green precipitate formed. The mixture was filtered and the green product was washed with ice-cold DMF 3 ml/3 times and dried under the vacuum. Yield: 0.89 g (74%). Anal, (Cu2C90H9OCI4N6O30) C, H5 N1 Cu: calcd, 53.92, 4.53, 4.19, 6.34; found: 53.68, 4.0S, 4.08, 6,61%. This synthesis resulted in a mixture of a dimer and a monomer as shown by EPR spectroscopy with ?30-40% of the copper present as the dimer and the rest as a monomer ("Product 1"). Similar reactions performed with somewhat more dilute solutions resulted in the precipitation of the monomer only as shown by EPR spectroscopy ("Product 2").Elemental microanalysesCopper analyses were performed with a varian AA-800 air-acetylene flame atomic absorption spectrophotometer. The C, H, N microanalyses were performed by the Department of Chemistry, University of Otago. EPO <DP n="29"/>Infrared spectroscopyFourier transform IR spectra were acquired from samples within pressed disks of KBr matrix on a Bio-Rad Win-IR FTS-40 infrared spectrometer (400-4000 cm- 1).UV-Vis spectroscopyDiffuse-reflectance solid-state UV-Vis spectra were recorded using a Varian Cary IE spectrophotometer. UV-Vis spectra of solutions were obtained in 1-cm quartz cells in a Hewlett-Packard 8452A diode-array (190-820 nm) or a Varian Cary 5E UV-VIS-NIR spectrophotometer. Each complex was dissolved in the same solvent as its solvent ligand.X-Band electron paramagnetic resonance spectroscopyX-band (?9.5 GHz) EPR spectra of powdered and solution samples of the complexes were acquired using a Bruker EMX EPR spectrometer equipped with a standard ER4120 X-band cavity, EMX 03SM NMR gaussmeter, EMX 032 field controller, EMX 08I magnet power supply, Bruker EMMX 048T microwave bridge control, and BVT2000 variable temperature unit.ResultsFigure 1 compares the infrared spectra of the reactants, copper(ll) acetate (a) and ACMH (c), and Product 1 (b). It is clear from the spectrum for Product 1 that the ACM ligand is bound to the metal, since many of the ACM bands that are not in copper acetate are in Product 1 and additionally, some bands change on the ACMH ligand due to its deprotoriation and coordination to the Cu(II) (notably the loss of the carboxylic acid O-H stretch above 2,000 cm- 1 and the large changes in the peaks due to the carbonyl group of carboxylic acid/carboxylate). The UV/Vis absorption spectra (Figure 2) of Product 1 in DMF (b) and [Cu2(Indo)4(DMA)2] in DMA (a), shows the intensity of the band in the UV/Vis for Product 1 is about half that for the Indo complex, whereas the ligand-centred bands are of comparable intensities. These results show that while the Indo complex is almost completely dimeric in DMA, Product 1 is almost completely monomeric in solution in DMF. The same result is EPO <DP n="30"/>obtained if the dissolved complex is Product 1 or Product 2 showing a rapid interconversion in solution. The spectrum also demonstrates that the structure of the monomer is a tetragonally distorted octahedron. The structure of the Cu-monomer complex, was established from the lack of Cu-dimer signals in the EPR spectrum of Product 2 (Figure 3) compared with the spectrum of Product 1 (Figure 4), which shows dimer peaks, which are inherently weaker than that of the monomer, and even though the monomer signal appears to dominate the spectrum, it contains substantial amounts of dimer. By comparison of the peak ratios of the monomer and dimer with those reported for Cu-lndo dimers and related species, the percentage of Cu as the dimer in Product 1 is estimated to be ?30-40% with the rest present as the monomer.
  • 20
  • [ 288-32-4 ]
  • copper(II) acetate [ No CAS ]
  • [ 53164-05-9 ]
  • bis(O,O'-acemetacin)bis(imidazole)copper(II) [ No CAS ]
YieldReaction ConditionsOperation in experiment
In methanol; water; for 0.416667h; Bis(O,O '-<strong>[53164-05-9]acemetacin</strong>)bis(imidazole)copper(Il); ([Cu(ACM)2(Im)2])[Cu(ACM)2(Im)2] was prepared by dissolving Cu acetate monohydrate (0.559 mmol, 0.1116 g) in MeOH (8 mL) with 12 drops of water and sonication of the mixture for 5 min. Accmetacin (1.118 mmol, 0.465 g) and imidazole (1.118 mmol, 0.076 g) were dissolved in MeOH (12 rnL), the copper solution was added dropwise and the mixture was stirred for 20 min. A colour change from green to blue to purple was followed by a copious precipitate within minutes. This was filtered, washed once with MeOH (3 mL) and the solid was dried at RT under N2. Anal.Found: C, 56.01; H, 4.11; N, 8.16; CaIc. for CuC48H42Cl2N6O12: C, 56.01 ; H, 4,11; N, 8.17.
  • 21
  • [ 557-34-6 ]
  • [ 7732-18-5 ]
  • [ 53164-05-9 ]
  • bis(O,O'-acemetacin)diaquzinc(II) [ No CAS ]
YieldReaction ConditionsOperation in experiment
In ethanol; at 60℃; EXAMPLE 3:; Diaquabis(O,O'- <strong>[53164-05-9]acemetacin</strong>)zinc(ll)-6-water ([Zn(ACM)2(OH2)2]-6H2O)The [Zn(ACM)4(OH2)2] complex was prepared in a way similar to that used in preparation of the [Cu2(ACM)4(OH2)2] complex. <strong>[53164-05-9]Acemetacin</strong> (2.079 g, 0.01 mol) was dissolved in ethanol (25 mL) with gradual heating to ~60C. Zn acetate dihydrate (0.504 g, 0.005 mol) was similarly dissolved in ethanol (25 ml) with continuous stirring and the solution was added to the <strong>[53164-05-9]acemetacin</strong> solution, followed by an additional 75 ml of ethanol. The resultant precipitate was filtered, washed with ethanol and dried. Anal Found: C, 52.41, ; H, 4.38; N, 2.81 ; CaIc. for [ZnC42H38Cl2N2O14.6H2O: C, 52.16; H, 4.38; N, 2,9.
  • 22
  • copper(II) acetate [ No CAS ]
  • [ 7732-18-5 ]
  • [ 53164-05-9 ]
  • bis(O,O'-acemetacin)diaquacopper(II) [ No CAS ]
YieldReaction ConditionsOperation in experiment
In ethanol; at 20 - 40℃; EXAMPLE 2:; Monomeric Cu(II) complexesBis(O,O'-<strong>[53164-05-9]acemetacin</strong>)diaquacopper(lI)-3-water ([CU(ACM)2(OH2)2].3H2O)ExperimentalThe [Cupsilon(ACM)2(OH2)2] monomer complex can be prepared as described for the Indo aqua dimer in Anti-Inflammatory Dinuclear Copper(II) Complexes with lndomethacin. Synthesis, Magnetism and EPR Spectroscopy; Crystal Structure of the N,N-Dimethylformamide Adduct. Weder, J. E,; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; MacLachlan, D.; Bramley, R.; Delfs, C. D.; Murray, K. S.; Moubaraki, B.; Warwick, B.; Biffin, J. R.; Regtop, H. L. Inorg. Chem. 1999, 38, 1736-1744, or more preferably, as follows. Cu(II) acetate monohydrate (1 g, 0.005 mmol) in ethanol (50 ml) was added drop wise to <strong>[53164-05-9]acemetacin</strong> (4.158 g, 0.01 mmol) dissolved in ethanol (50ml) at room temperature. Warming the ethanol mildly (~40 C) helped solubilise the <strong>[53164-05-9]acemetacin</strong> before adding the copper acetate solution. On addition of the Cu(II) acetate monohydrate in ethanol, a bright green complex started to form immediately. To this,150 ml of ethanol was added and left stirring overnight, during which time it converts to a blue complex. Following this, the precipitate was filtered, washed with ethanol and dried. Anal. Found: C, 54.35; H, 3.88; Nu, 3.06; Cu, 6.82; Cl, 7.60%. CaIc. for CuC42H38CI2N2O14: C, 54.3; H, 4.12; N, 3.01; Cu, 6.84, Cl 7.60 %.
  • 23
  • [Co(NH3)5(OSO2CF3)](CF3SO3)2 [ No CAS ]
  • [ 53164-05-9 ]
  • pentaammine(acemetacin)cobalt(III) bis(trifluoromethanesuIfonate) [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In dimethyl sulfoxide; at 50 - 80℃; for 5.0h; EXAMPLE 4:; Pentaammine(<strong>[53164-05-9]acemetacin</strong>)cobalt(Ill) trifluoromethanesuIfonate-2-dimethylsulfoxide ([Co(NH3)5(ACM)](SO3CF3)2.2(CH3)2SO)The [Co(NH3)5(ACM)](SO3CF3)2 complex using the general method described in Ion Association und the Reactions of Cobalt(III)-Acido complexes. 4. Origin of the Products in the Base Hydrolysis of [Co(NH3)5X](3-n) Complexes. Brasch, N E.; Buckingham, D.A.; Clark, C.R.; Finnie, K.S. Inorg. Chem. 1989, 238, 4567- 4574._[Co(NH3)5(OSO2CF3)](CF3SO3)2, (0.84 ol, m 0m,5 g) was slowly added to excess <strong>[53164-05-9]acemetacin</strong> (2.8 mmol, 1.16 g) in triethylamine (2.8 mmol, 0.38 ml) and EPO <DP n="33"/>DMSO (5 ml), and the mixture was stirred over an oil bath for 3 hr at 50 C. The solution was then heated to 80 C for 2 hr. It was cooled and slowly added to diethyl ether (800 ml) with brisk stirring. The oily residue was stirred for an hour, the cloudy diethyl ether was replaced with fresh diethyl ether and the mixture was refrigerated overnight. It was sonicated for 10 minutes resulting in formation of a red solid, which was filtered and dried under vacuum. Anal. Found: C, 31.9; H, 4.16; N, 8.26; CaIc. for CoC27H44ClN6O14S4F6: C, 32,00; H, 4.38; N, 8.30.
YieldReaction ConditionsOperation in experiment
(a) 3.4 g of dinitrogen tetroxide from a bomb are condensed, in the absence of moisture (Siccopent tube), in a cold trap with a narrow syphon tube, and are diluted to 12 ml with cold absolute tetrahydrofuran (blue solution). 2.4 g (0.005 mol) of the acemetacin derivative are dissolved in 5 ml of flacial acetic acid, 5 ml of absolute dioxane and 1.64 g (0.02 mol) of sodium acetate are added, and the mixture is cooled to 0 C. while stirring. Thereafter, 3.3 ml of the solution a) are added dropwise at 0 C., and the mixture is allowed to react for 2 hours at this temperature (quantitative conversion of the acemetacin derivative). The reaction mixture is poured onto ice and extracted with cold ether. The ether phase is washed thoroughly with ice-cold water, ice-cold potassium bicarbonate solution and ice-water in succession, dried over MgSO4, filtered, and concentrated to 80 ml at 0 C. in a rotary evaporator. 0.7 g (0.005 mol) of potassium carbonate (finely powdered) is then added, and the mixture is brought to reaction for 3 hours at 0 C., while stirring and in the absence of moisture. The quantity of gas formed is collected in a gas burette (at 0 C.=165 ml; theory: 224 ml). When the mixture stands overnight at room temperature, substantial evolution of gas no longer takes place; however, a substance was precipitated, from which 700 mg of acemetacin were obtained after the ethereal solution had been decanted, the precipitate acidified with acetic acid and the mixture extracted with ethyl acetate. From the alkaline-aqueous mother liquor of the above ether extraction, a further 200 mg, mainly acemetacin, are obtained by acidification and extraction. These 900 mg are then chromatographed over silica gel using cyclohexane/ethyl acetate/glacial acetic acid (10:10:1).
  • 25
  • [ 98461-21-3 ]
  • [ 53164-05-9 ]
  • C39H60ClNO11Si4 [ No CAS ]
  • 26
  • [ 116539-58-3 ]
  • [ 53164-05-9 ]
  • [ 1309349-71-0 ]
YieldReaction ConditionsOperation in experiment
Example 1 : <strong>[53164-05-9]Acemetacin</strong>/(S)-duloxetine amorphous salt.; A solution of <strong>[53164-05-9]acemetacin</strong> (23.3 mg, 0.056 mmol, 1 eq) in 0.56 mL of tetrahydrofuran was added to a solution of (S)-duloxetine (16.7 mg, 0.056 mmol, 1 eq) in 0.36 mL of methanol. The mixture was evaporated to dryness, and the residue obtained was suspended in diisopropyl ether (2.8 mL) for 12 h at 50C. The oil obtained was separated from the solution and dried under vacuum for 4 h at 40C to give a pale yellow solid corresponding to the salt <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine.The <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine salt has been obtained from a hot saturated solution starting with a ratio of <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine of 1 :1. The salt has also been obtained starting with a ratio of <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine of 2:1 and 1 :2 in diisopropyl ether.Characterization of <strong>[53164-05-9]acemetacin</strong> / (S)-duloxetine amorphous salt1H NMR (400 MHz, ctt-methanol) delta: 2.29 (s, 3H), 2.39-2.48 (m, 1 H), 2.56-2.66 (m, 1 H), 2.71 (s, 3H), 3.16-3.23 (m, 1H), 3.27-3.34 (m, 1 H), 3.80 (s, 3H), 3.85 (s, 2H), 4.49 (s, 2H), 5.94 (dd, J = 8 Hz, J = 5 Hz, 1 H), 6.66 (dd, J = 9 Hz, J = 3 Hz, 1 H), 6.92-6.96 (m, 3H), 7.07 (d, J = 3 Hz, 1 H), 7.15 (d, J = 4 Hz, 1 H), 7.26 (t, J = 8 Hz, 1 H), 7.32 (d, J = 5 Hz, 1 H), 7.40 (d, J = 8 Hz, 1 H), 7.44-7.49 (m, 2H), 7.52 (d, J = 9 Hz, 2H), 7.65 (d, J = 9 Hz, 2H), 7.75-7.80 (m, 1 H), 8.27-8.31 (m, 1 H). DSC (10C/min): No endothermic peak was observed, (see figure 1 )TG (10C/min): A weight loss of 0.7% presumably corresponding to water and a weight loss of 1.7% corresponding to diisopropyl ether, as detected in the H-NMR. (see figure 1 )XRPD (see figure 2)
In tetrahydrofuran; methanol;Product distribution / selectivity; Example 1: <strong>[53164-05-9]Acemetacin</strong>/(S)-duloxetine amorphous salt. A solution of <strong>[53164-05-9]acemetacin</strong> (23.3 mg, 0.056 mmol, 1 eq) in 0.56 mL of tetrahydrofuran was added to a solution of (S)-duloxetine (16.7 mg, 0.056 mmol, 1 eq) in 0.36 mL of methanol. The mixture was evaporated to dryness, and the residue obtained was suspended in diisopropyl ether (2.8 mL) for 12 h at 50C. The oil obtained was separated from the solution and dried under vacuum for 4 h at 40C to give a pale yellow solid corresponding to the salt <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine. The <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine salt has been obtained from a hot saturated solution starting with a ratio of <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine of 1:1. The salt has also been obtained starting with a ratio of <strong>[53164-05-9]acemetacin</strong>/(S)-duloxetine of 2:1 and 1:2 in diisopropyl ether.Characterization of <strong>[53164-05-9]acemetacin</strong> / (S)-duloxetine amorphous salt 1H NMR (400 MHz, d4-methanol) delta: 2.29 (s, 3H), 2.39-2.48 (m, 1H), 2.56-2.66 (m, 1H), 2.71 (s, 3H), 3.16-3.23 (m, 1H), 3.27-3.34 (m, 1H), 3.80 (s, 3H), 3.85 (s, 2H), 4.49 (s, 2H), 5.94 (dd, J = 8 Hz, J = 5 Hz, 1H), 6.66 (dd, J = 9 Hz, J = 3 Hz, 1H), 6.92-6.96 (m, 3H), 7.07 (d, J = 3 Hz, 1H), 7.15 (d, J = 4 Hz, 1H), 7.26 (t, J = 8 Hz, 1H), 7.32 (d, J = 5 Hz, 1H), 7.40 (d, J = 8 Hz, 1H), 7.44-7.49 (m, 2H), 7.52 (d, J = 9 Hz, 2H), 7.65 (d, J = 9 Hz, 2H), 7.75-7.80 (m, 1H), 8.27-8.31 (m, 1H). DSC (10C/min): No endothermic peak was observed. (see figure 1) TG (10C/min): A weight loss of 0.7% presumably corresponding to water and a weight loss of 1.7% corresponding to diisopropyl ether, as detected in the 1H-NMR. (see figure 1) XRPD (see figure 2)
  • 27
  • [ 88192-19-2 ]
  • [ 53164-05-9 ]
  • C24H24ClN5O5 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With 1,1'-carbonyldiimidazole; In chloroform; To facilitate the conjugation of these small molecules to the polyacrylic acid-coated iron oxide nanoparticles, the small molecules were coupled to an azide linker (3-azide propylamine) through their respective carboxylic acid groups using carbonyldiimidazole chemistry yielding a series of 30 azide-conjugated small molecules (Table 3).
  • 28
  • [ 53164-05-9 ]
  • [ 259886-50-5 ]
  • C42H42N28O14*C21H18ClNO6 [ No CAS ]
YieldReaction ConditionsOperation in experiment
In water; General procedure: Due to the irregular trend in absorbance spectra we were unable toget the binding constant value by using the absorbance data. The interactionbetween the IMC and ACMdrug moleculewith host can be quantitativelyestimated directly from the fluorescence measurement inorder to get strength of the host-guest interaction between IMC andACM with CB7, respectively. The binding constant value obtained fromfluorescence data represents the binding strength in excited state. Inour study we found that 1:1 complex is formed for both the drug moleculeswith macrocyclic host CB7.
  • 29
  • [ 1601-20-3 ]
  • [ 64-19-7 ]
  • [ 53164-05-9 ]
YieldReaction ConditionsOperation in experiment
98.8% With hydrogenchloride; aluminum (III) chloride; at 60℃; for 5.0h;Large scale; 50 kg of acetic acid into the reaction tank,Stirring into the hydrogen chloride,The content of hydrogen chloride (w / w) was 16%.Adding aluminum trichloride 2.0 Kg,Acemetacin t-butyl 100KG,The temperature was stirred at 60 C for 5 hours,Cooling to 20 ,Standing for 2 hours to complete crystallization, filtration, washing the top, 80 deg.] C and drying, to obtain 82.1 kg acemetacin, yield 93.19%. The crude product dissolved in 360 kg of toluene, heated to dissolve, put into the activated carbon 1 kg, stirring for 20 minutes, pumping, cooling to room temperature, standing for 2 hours to complete crystallization, filtration, a small amount of toluene washing, dry,It was 80.5 kg acemetacin Competitive product .The yield of the solution was 98.8%.
  • 30
  • [ 38780-40-4 ]
  • [ 53164-05-9 ]
  • C27H31Cl2N3O6Pt [ No CAS ]
YieldReaction ConditionsOperation in experiment
53% With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24.0h;Darkness; Cis-dichloro-1,2-cyclohexanediamine platinum(190 mg), AgNO3 (43 mg), <strong>[53164-05-9]acemetacin</strong> (207.9 mg) andNa2C03 (35.3 mg) was added to the round bottom flask followed by 10 ml of DMF, Stirring at room temperature for 24 h against light. AgCl discarded by centrifugationprecipitationAfter the filtrate was concentrated, 50 ml of ethyl acetate was added, Then washed with 50ml 0.1M Na2C03 three times, washed three times, collecting acetic acidEthyl ester layer and dried over anhydrous sodium sulfate overnight. filter, The filtrate with methanol: chloroform = 1: 9 eluent, silica gel column chromatographyAsimi cinxin-cyclohexanediamine platinum complex was obtained in a yield of 53%, The formula is shown in formula 44 below
  • 31
  • [ 75302-98-6 ]
  • [ 53-86-1 ]
  • [ 53164-05-9 ]
YieldReaction ConditionsOperation in experiment
30%; 66% With iodine; aluminium; In acetonitrile; at 20℃; for 6.0h; To a suspension of AlI3 (2.0 mmol) in acetonitrile (20 mL) was charged ester 20 (0.943 g, 2.0 mmol). The mixture was stirred for 6h at 20 oC. After quenchingwith 2 M HCl (10 mL), the mixture was extracted by EA (50 mL × 3). The combined organic phase was washed with saturated aqueous Na2S2O3 (10 mL) to remove elementiodine. After evaporation of organic solvents, the residue was purified by flash column chromatography (PE/EA 3:2, EA was acidified with 1% formic acid) to afford indometacin22 (0.209 g, 30%) as a minor product, and 24 (0.554 g, 66%) as a yellow solid
 

Historical Records

Categories